With millions of people impacted by neurological disorders, more research is urgently needed to advance science in this area. The Alkermes Pathways Research Awards® program is designed to support the next generation of researchers who are working on the front lines to advance our understanding of diseases in the field of neuroscience.
The Alkermes Pathways Research Awards program provides opportunities for individual grants of up to $100,000 per research project for early-career investigators focused on research relating to schizophrenia or bipolar disorder.
Craig Hopkinson,
Chief Medical Officer and Executive Vice President, Research & Development
All applications will be formally reviewed by an Independent Review Committee comprising prominent researchers in the relevant field. The Review Committee has final responsibility for selection of Awardees.
When the Review Committee evaluates a proposal, they will consider criteria, including but not limited to overall impact, candidate, mentor, environment and institutional commitment to the applicant and research plan.
Note that applications are not required to include an Alkermes product.
To be eligible, an applicant must meet the following criteria:
The following items should be included in the submission:
Pathways Guidance Pathways Application Supplement Pathways Budget Form
Application period opens: Sept. 20, 2024
Application deadline: Nov. 30, 2024 (by 11:59 p.m. ET)
Notification of Review Committee decision: Q2 2025
Public announcement of awardees: 2H 2025